CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy

[1]  M. Ratain,et al.  Pharmacogenetics in cancer treatment. , 2003, Annual review of medicine.

[2]  P. Beaune,et al.  Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12 , 2003, Transplantation.

[3]  R. Kim,et al.  Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. , 2003, Pharmacogenetics.

[4]  K. Thummel.  Does the CYP3A5*3 polymorphism affect in vivo drug elimination? , 2003, Pharmacogenetics.

[5]  P. Watkins,et al.  CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. , 2003, Journal of applied physiology.

[6]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[7]  M. Boiocchi,et al.  Pharmacogenetics of irinotecan. , 2003, Current medicinal chemistry. Anti-cancer agents.

[8]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[9]  Jin‐ding Huang,et al.  Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[11]  B. Goh,et al.  Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[13]  H. Gurney,et al.  How to calculate the dose of chemotherapy , 2002, British Journal of Cancer.

[14]  Ann Daly,et al.  Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. , 2002, Pharmacogenetics.

[15]  P. Watkins,et al.  In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. , 2001, Pharmacogenetics.

[16]  Jin‐ding Huang,et al.  Genetic polymorphism of cytochrome P450 3A5 in Chinese. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[17]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[18]  U. Brinkmann,et al.  Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. , 2001, Pharmacogenetics.

[19]  D E Johnston,et al.  Special considerations in interpreting liver function tests. , 1999, American family physician.

[20]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[21]  G. Gasbarrini,et al.  Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients , 1998, Journal of gastroenterology and hepatology.

[22]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[24]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[25]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  S D Hall,et al.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.

[27]  M. Relling,et al.  O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. , 1994, Molecular pharmacology.

[28]  X. J. Zhou,et al.  Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. , 1993, Cancer research.

[29]  X. J. Zhou,et al.  Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. , 1993, Biochemical pharmacology.

[30]  G. Strain,et al.  The relationship of weight-height indices of obesity to body fat content. , 1992, Journal of the American College of Nutrition.

[31]  A. Cassano,et al.  Antipyrine metabolism in patients with liver metastases from colorectal cancer , 1992, Cancer.

[32]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[33]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[34]  R. Rahmani,et al.  Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. , 1988, Biochemical pharmacology.

[35]  J. Cano,et al.  Involvement of the macrolide antibiotic inducible cytochrome P-450 LM3c in the metabolism of midazolam by microsomal fractions prepared from rabbit liver. , 1988, Biochemical pharmacology.

[36]  P. Rissanen,et al.  The Steady-State Pharmacokinetics of Tamoxifen and its Metabolites in Breast Cancer Patients , 1986, The Journal of international medical research.

[37]  P. Vrignaud,et al.  Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. , 1985, Cancer treatment reports.

[38]  S. Kliewer,et al.  Regulation of cyp3a gene transcription by the pregnane x receptor. , 2002, Annual review of pharmacology and toxicology.

[39]  E. Schuetz,et al.  G enetic contribution to variable human CYP 3 A-mediated metabolism , 2002 .

[40]  A. Fraser,et al.  Urinary screening for midazolam and its major metabolites with the Abbott ADx and TDx analyzers and the EMIT d.a.u. benzodiazepine assay with confirmation by GC/MS. , 1991, Journal of analytical toxicology.

[41]  E. F. Du Bois,et al.  A formula to estimate the approximate surface area if height and weight be known. 1916. , 1989, Nutrition.